GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Piotroski F-Score

ATAI Life Sciences NV (ATAI Life Sciences NV) Piotroski F-Score : 2 (As of Apr. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ATAI Life Sciences NV has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ATAI Life Sciences NV's Piotroski F-Score or its related term are showing as below:

ATAI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 2   Max: 7
Current: 2

During the past 5 years, the highest Piotroski F-Score of ATAI Life Sciences NV was 7. The lowest was 2. And the median was 2.


ATAI Life Sciences NV Piotroski F-Score Historical Data

The historical data trend for ATAI Life Sciences NV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Piotroski F-Score Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 7.00 2.00 2.00

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 1.00 2.00 2.00

Competitive Comparison of ATAI Life Sciences NV's Piotroski F-Score

For the Biotechnology subindustry, ATAI Life Sciences NV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -33.135 + -33.042 + 44.244 + -18.292 = $-40.23 Mil.
Cash Flow from Operations was -21.111 + -22.614 + -18.431 + -21.962 = $-84.12 Mil.
Revenue was 0.037 + 0.172 + 0.087 + 0.018 = $0.31 Mil.
Gross Profit was 0.037 + 0.172 + 0.087 + 0.018 = $0.31 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(305.441 + 280.717 + 253.595 + 308.22 + 293.478) / 5 = $288.2902 Mil.
Total Assets at the begining of this year (Dec22) was $305.44 Mil.
Long-Term Debt & Capital Lease Obligation was $18.87 Mil.
Total Current Assets was $185.59 Mil.
Total Current Liabilities was $20.12 Mil.
Net Income was -36.869 + -36.618 + -33.887 + -45.011 = $-152.39 Mil.

Revenue was 0 + 0.17 + 0.024 + 0.038 = $0.23 Mil.
Gross Profit was 0 + 0.17 + 0.024 + 0.038 = $0.23 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(414.166 + 383.732 + 348.936 + 342.597 + 305.441) / 5 = $358.9744 Mil.
Total Assets at the begining of last year (Dec21) was $414.17 Mil.
Long-Term Debt & Capital Lease Obligation was $15.16 Mil.
Total Current Assets was $287.15 Mil.
Total Current Liabilities was $19.90 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ATAI Life Sciences NV's current Net Income (TTM) was -40.23. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ATAI Life Sciences NV's current Cash Flow from Operations (TTM) was -84.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-40.225/305.441
=-0.13169483

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-152.385/414.166
=-0.36793218

ATAI Life Sciences NV's return on assets of this year was -0.13169483. ATAI Life Sciences NV's return on assets of last year was -0.36793218. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ATAI Life Sciences NV's current Net Income (TTM) was -40.23. ATAI Life Sciences NV's current Cash Flow from Operations (TTM) was -84.12. ==> -84.12 <= -40.23 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=18.867/288.2902
=0.06544447

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=15.161/358.9744
=0.04223421

ATAI Life Sciences NV's gearing of this year was 0.06544447. ATAI Life Sciences NV's gearing of last year was 0.04223421. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=185.592/20.12
=9.22425447

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=287.145/19.897
=14.4315726

ATAI Life Sciences NV's current ratio of this year was 9.22425447. ATAI Life Sciences NV's current ratio of last year was 14.4315726. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ATAI Life Sciences NV's number of shares in issue this year was 167.954. ATAI Life Sciences NV's number of shares in issue last year was 158.737. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.314/0.314
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.232/0.232
=1

ATAI Life Sciences NV's gross margin of this year was 1. ATAI Life Sciences NV's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.314/305.441
=0.00102802

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.232/414.166
=0.00056016

ATAI Life Sciences NV's asset turnover of this year was 0.00102802. ATAI Life Sciences NV's asset turnover of last year was 0.00056016. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ATAI Life Sciences NV has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

ATAI Life Sciences NV  (NAS:ATAI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ATAI Life Sciences NV Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014